Xconomy | Boston - Business + Technology in the Exponential Economy

Avant Changes Name to Celldex Therapeutics, Hires Marucci as Permanent CEO

Avant Immunotherapeutics said today it is changing its name to Celldex Therapeutics as part of the merger the two companies announced in the first quarter. The Needham, MA-based company (NASDAQ: AVAN) will change its ticker symbol to (NASDAQ: CLDX), starting Oct. 1. The company’s board also announced that Anthony Marucci, who has worked as interim CEO since May, has gotten the job on a permanent basis. Celldex is developing antibody drugs to deliver vaccines directly to their therapeutic targets.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: